Novopharm Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 03-07-2024
- Paid Up Capital ₹ 0.47 M
as on 03-07-2024
- Company Age 22 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 20.00 M
as on 03-07-2024
- Revenue 13.66%
(FY 2022)
- Profit 32.38%
(FY 2022)
- Ebitda 27.19%
(FY 2022)
- Net Worth 27.73%
(FY 2022)
- Total Assets 32.68%
(FY 2022)
About Novopharm Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.47 M.
The company currently has active open charges totaling ₹2.00 Cr.
Rajeev Anand, Harpreet Arora, and Lakhvinder Arora serve as directors at the Company.
- CIN/LLPIN
U24231DL2002PTC114142
- Company No.
114142
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Feb 2002
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
West Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Novopharm Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Harpreet Arora  | Director | 07-Feb-2002 | Current |
| Rajeev Anand | Director | 01-May-2008 | Current |
| Lakhvinder Arora | Director | 07-Feb-2002 | Current |
Financial Performance and Corporate Structure Insights of Novopharm Life Sciences.
Novopharm Life Sciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 13.66% increase. The company also saw a substantial improvement in profitability, with a 32.38% increase in profit. The company's net worth Soared by an impressive increase of 27.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novopharm Life Sciences?
In 2020, Novopharm Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Novomax Pharma Private Limited
Active 12 years 4 monthsRajeev Anand, Harpreet Arora and 1 more are mutual person
M H Medicus Private Limited
Active 20 years 6 monthsHarpreet Arora and Lakhvinder Arora are mutual person
Panchdeep Medi-Care Private Limited.
Active 32 years 10 monthsHarpreet Arora and Lakhvinder Arora are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 18 Nov 2021 | ₹2.00 Cr | Open |
How Many Employees Work at Novopharm Life Sciences?
Unlock and access historical data on people associated with Novopharm Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novopharm Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novopharm Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
